Consolidated Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Consolidated Statements of Operations [Abstract]
Grant revenue	$ 796,000	$ 1,236,000
Operating expenses
Research and development	9,604,000	8,028,000
General and administrative	2,538,000	1,983,000
Total operating expenses	12,142,000	10,011,000
Loss from operations	(11,346,000)	(8,775,000)
Other income (expense)
Interest income	18,000	1,000
Change in fair value of convertible debt	(3,162,000)
Total other income (expense), net	(3,144,000)	1,000
Net loss	$ (14,490,000)	$ (8,774,000)
Net Loss per Share
Net loss per share, basic	$ (0.40)	$ (0.30)
Net loss per share, diluted	$ (0.40)	$ (0.30)
Weighted average shares outstanding, basic	36,045,040	28,996,499
Weighted average shares outstanding, diluted	36,045,040	28,996,499